Previous 10 | Next 10 |
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at Baird’s 20...
ICON Public Limited Company (ICLR) Q2 2019 Earnings Conference Call July 25, 2019 10:00 AM ET Company Participants Jonathan Curtain - Vice President, Corporate Finance & Investor Relation Brendan Brennan - Chief Financial Officer Steve Cutler - Chief Executive Officer Conf...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2019 Q2 earnings Read more ...
Icon (NASDAQ: ICLR ): Q2 GAAP EPS of $1.69 beats by $0.01 . More news on: ICON Public Limited Company, Earnings news and commentary, Healthcare stocks news, Read more ...
Highlights Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30. Quarter 2 reported revenue of $695.1 million. This represents a year on year increase of 8.3% or 10.5% on a constant currency basis. Reported earnin...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Ms. Julie O’Neill as a non-executive director. Ms. O’Neill is an ...
ICON plc (NASDAQ: ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 23, 2019 (which resolutions ...
Thesis Icon (NASDAQ: ICLR ) is a leading CRO company in terms of revenues that has the potential to maintain double-digit growth rates taking advantage of industry trends. The CRO market is expected to keep growing as more and more R&D will be outsourced by pharma companies like Icon...
Social media and news aggregation site will highlight real-time digital conversations at DIA 2019 ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today annou...
Acquisition enhances ICON’s patient access in Europe and Africa ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a m...
News, Short Squeeze, Breakout and More Instantly...
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 20...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclus...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...